10-Q: Entera Bio Reports First Quarter 2025 Financial Results and Provides Business Update

Entera Bio Ltd. reports its financial results for the first quarter of 2025, highlighting progress in its clinical programs and a new collaboration agreement with OPKO.

Summary

• Entera Bio Ltd. reported a net loss of $2.6 million, or $0.06 per share, for the three months ended March 31, 2025, compared to a net loss of $2.0 million, or $0.05 per share, for the same period in 2024.
• The company's cash and cash equivalents, including restricted cash, totaled $20.6 million as of March 31, 2025.
• Entera Bio believes its current cash resources will be sufficient to fund operations through the middle of the third quarter of 2026.
• A new collaboration agreement was established with OPKO for the development of an oral GLP-1/Glucagon dual agonist.
• The company issued 3,685,226 ordinary shares to OPKO for $8.0 million in connection with the collaboration agreement.
• Entera Bio is preparing to initiate a Phase 3 registrational study for EB613 for osteoporosis.
• The company is also developing EB612 as an oral treatment for hypoparathyroidism.
• Revenues for the three months ended March 31, 2025 were $42 thousand, attributable to research services.
• Research and development expenses for the three months ended March 31, 2025 were $1.1 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is making progress with its clinical programs and has secured a collaboration agreement, it is still operating at a loss and requires additional funding.

Positives

• The company's cash position of $20.6 million is expected to fund operations through the middle of the third quarter of 2026.
• The collaboration agreement with OPKO provides funding and expertise for the development of an oral GLP-1/Glucagon dual agonist.
• The company is progressing towards a Phase 3 study for EB613, a potential treatment for osteoporosis.
• Entera Bio is expanding its pipeline with EB612 for hypoparathyroidism.
• The company generated $42 thousand in revenue from research services.

Negatives

• The company reported a net loss of $2.6 million for the first quarter of 2025.
• The company has an accumulated deficit of $116.5 million as of March 31, 2025.
• The company's ability to commence the Phase 3 program of EB613 in osteoporosis will depend on finalizing discussions with the FDA and will require additional funding, which may not be available on reasonable terms, or at all.

Risks

• Clinical development involves a lengthy and expensive process with uncertain outcomes.
• Regulatory approval processes are lengthy, time-consuming and unpredictable.
• Preclinical development is uncertain and may not advance to clinical trials.
• Positive results from preclinical studies and early-stage clinical trials may not be predictive of future results.
• The company's estimates regarding expenses, capital requirements, and the sufficiency of cash resources may be inaccurate.
• The company's ability to continue as a going concern is dependent on access to sources of liquidity.
• The company's ability to raise additional funds or consummate strategic partnerships may not be available on acceptable terms or at all.
• Even if a product candidate receives marketing approval, it may fail to achieve market acceptance.
• Failure to obtain or maintain coverage and adequate reimbursement for product candidates could limit the ability to market those products and decrease the ability to generate revenue.
• The company relies on third parties to conduct clinical trials and on third-party suppliers to supply or produce product candidates.
• The company's competitive position with respect to other products on the market or in development may impact its success.
• The company's ability to obtain, maintain and protect its intellectual property and operate its business without infringing on the rights of others is critical.
• The company's ability to retain key personnel and recruit additional qualified personnel is important for its success.
• The duration and intensity of the ongoing Israel-Hamas War, and escalation of Hezbollah's conflict since October 2023 as well as the developing conflict with Iran and its proxies in the Middle East, such as the Houthis in Yemen and militias in Iraq and Syria, and their impact on our operations and workforce.

Future Outlook

Entera Bio believes its current cash resources will be sufficient to meet its projected operating requirements through the middle of the third quarter of 2026, excluding the initiation of the Phase 3 program of EB613 in osteoporosis, which will require additional funding.

Management Comments

• Management continually evaluates various financing alternatives and strategic collaborations, as the Company will need to finance future research and clinical development with additional capital.

Industry Context

Entera Bio is focused on developing oral tablet formats of peptide or protein replacement therapies, addressing the challenges of oral delivery for these types of drugs. The collaboration with OPKO leverages their expertise in GLP-1/Glucagon agonists, positioning Entera Bio in the competitive landscape of obesity and metabolic disorder treatments.

Comparison to Industry Standards

• The development of oral peptide treatments is a significant challenge in the pharmaceutical industry, with few successful products currently available.
• Novo Nordisk's Rybelsus is an example of an oral GLP-1 receptor agonist, demonstrating the potential for oral peptide therapies in the treatment of diabetes.
• Entera Bio's N-Tab technology aims to improve the oral bioavailability of peptides, addressing a key limitation of traditional injectable formulations.
• The collaboration with OPKO to develop an oral GLP-1/Glucagon dual agonist positions Entera Bio in the competitive market for obesity and metabolic disorder treatments, alongside companies like Eli Lilly and Novo Nordisk.

Related Party Transactions

• The company issued 40,993 ordinary shares to five non-executive members of the board of directors in lieu cash board fees for the fourth quarter of 2024.
• The company issued 3,685,226 ordinary shares to OPKO for $8.0 million in connection with the collaboration agreement.

Stakeholder Impact

• Shareholders: Dilution may occur if the company raises additional capital through equity offerings.
• Employees: The company's ability to continue as a going concern depends on securing additional funding.
• Patients: The company is developing potential new treatments for osteoporosis and hypoparathyroidism.

Next Steps

• The company is preparing to initiate a Phase 3 registrational study for EB613 for osteoporosis.
• The company plans to file an Investigational New Drug (IND) application with the FDA later this year for the oral OXM program.

Key Dates

Keywords

EB613, EB612, osteoporosis, hypoparathyroidism, oral PTH, OPKO, GLP-1, Glucagon, N-Tab technology, clinical trials, financial results, Entera Bio